Publication | Closed Access

Comparison of thrice-daily premixed insulin (insulin lispro premix) with basal-bolus (insulin glargine once-daily plus thrice-daily prandial insulin lispro) therapy in east Asian patients with type 2 diabetes insufficiently controlled with twice-daily premixed insulin: an open-label, randomised, controlled trial

Metabolic SyndromeDiabetes ManagementInsulin ManagementDiabetesType 2Thrice-daily Premixed InsulinDiabetes MellitusInsulin DeliveryEast Asian PatientsMedicine